Clinical association between coagulation indicators and bone metastasis in patients with gastric cancer

doi:10.4251/wjgo.v15.i7.1253

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2522)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

WORD

HTML

1110

Figures (1-1)

168

Tables (1-3)

211

Sum=1585

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

174

Download

686

Sum=860

Jul 15, 2023 (publication date) through Nov 27, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Jul 15, 2023; 15(7): 1253-1261
Published online Jul 15, 2023. doi: 10.4251/wjgo.v15.i7.1253

Table 1 Demographic and baseline characteristics of patients

Characteristic	Overall, n = 454	No bone metastasis, n = 263	Bone metastasis, n = 191	P value
Male sex	335 (73.8)	196 (74.5)	139 (72.8)	0.676
Age, yr	59 (50-67)	61 (51-67)	57 (49-66)	0.046
CEA, ng/mL	3.53 (1.73-14.65)	2.43 (1.35-4.89)	5.29 (2.90-38.31)	< 0.001
CA19-9, U/mL	12.25 (6.30-46.88)	9.89 (4.92-20.20)	22.62 (9.73-113.35)	< 0.001
CA72-4, U/mL	3.39 (1.60-12.00)	2.58 (1.57-6.78)	7.09 (1.96-21.68)	< 0.001
Erythrocyte, × 10¹²/L	4.14 (3.65-4.57)	4.27 (3.78-4.68)	4.00 (3.50-4.39)	< 0.001
Hemoglobin, g/L	124 (106-139)	127 (109-143)	119 (103-133)	< 0.001
Leukocyte, × 10⁹/L	5.69 (4.51-7.12)	5.51 (4.43-6.76)	6.20 (4.69-7.86)	0.002
Neutrophil, × 10⁹/L	3.54 (2.64-4.88)	3.23 (2.51-4.33)	4.04 (2.83-5.97)	< 0.001
Lymphocyte, × 10⁹/L	1.37 (1.08-1.81)	1.48 (1.12-1.95)	1.30 (1.02-1.63)	0.001
Platelet, × 10⁹/L	196 (150-253)	204 (160-260)	180 (140-235)	0.001
Monocyte, × 10⁹/L	0.41 (0.30-0.54)	0.42 (0.31-0.54)	0.40 (0.30-0.55)	0.713
Glucose, mmol/L	4.54 (4.17-5.07)	4.40 (4.04-4.83)	4.84 (4.39-5.55)	< 0.001
Albumin, g/L	38.11 ± 4.96	37.80 ± 4.71	38.55 ± 5.26	0.113
Globulin, g/L	26.4 (23.7-29.8)	25.5 (22.8-28.2)	28.8 (25.1-31.6)	< 0.001
PT, s	13.1 (12.5-13.8)	12.8 (12.3-13.4)	13.5 (13.0-14.4)	< 0.001
PTR	1.05 (0.99-1.10)	1.03 (0.98-1.08)	1.06 (1.01-1.12)	< 0.001
INR	1.05 (0.99-1.10)	1.03 (0.98-1.08)	1.07 (1.01-1.13)	< 0.001
aPTT, s	35.0 (31.5-38.1)	33.5 (30.8-36.8)	36.3 (33.7-39.1)	< 0.001
TT, s	16.3 (15.6-16.9)	16.4 (15.7-17.0)	16.0 (15.3-16.8)	< 0.001
FIB, g/L	3.32 (2.76-4.16)	3.21 (2.62-3.82)	3.63 (2.93-4.59)	< 0.001
D-dimer, mg/L	0.9 (0.3-2.5)	0.5 (0.1-1.1)	2.0 (0.8-6.6)	< 0.001
FDP, mg/L	1.9 (0.9-4.9)	1.2 (0.7-2.5)	4.5 (1.7-16.2)	< 0.001

Data are shown as number of cases and percentage or median and interquartile range. aPTT: Activated partial prothrombin time; CA19-9: Carbohydrate antigen 19-9; CA72-4: Carbohydrate antigen 72-4; CEA: Carcinoembryonic antigen; FDP: Fibrin degradation products; FIB: Fibrinogen; INR: International normalized ratio; PT: Prothrombin time; PTR: Prothrombin ratio; TT: Thrombin time.

Citation: Wang X, Wang JY, Chen M, Ren J, Zhang X. Clinical association between coagulation indicators and bone metastasis in patients with gastric cancer. World J Gastrointest Oncol 2023; 15(7): 1253-1261
URL: https://www.wjgnet.com/1948-5204/full/v15/i7/1253.htm
DOI: https://dx.doi.org/10.4251/wjgo.v15.i7.1253